Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neramexane Monotherapy in Moderate to Severe Alzheimer's Disease
NCT00090116Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Mar 2003
- Primary completion
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of neramexane in Alzheimer's disease (AD), sponsored by Forest Laboratories. Started Mar 2003; status: completed.
02
Drugs
neramexane
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00090116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00090116.